Dr. Morgan on Olaparib for Metastatic Castration-Resistant Prostate Cancer
Alicia Morgan, MD
Alicia Morgan, MD, Mather Hospital, discusses the role of olaparib (Lynparza) for patients with metastatic castration-resistant prostate cancer (mCRPC).
Olaparib is a PARP inhibitor for the treatment of patients with mCRPC. In the TOPARP-A study, men were selected if they had undergone multiple prior therapies and were treatment refractory, explains Morgan. The response rate of patients who had DNA repair defects was 88%, based on prostate-specific antigen (PSA) response.
According to Morgan, the response was higher than what is traditionally expected in a regular clinical trial.